Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Sep 28, 2008; 14(36): 5549-5556
Published online Sep 28, 2008. doi: 10.3748/wjg.14.5549
Published online Sep 28, 2008. doi: 10.3748/wjg.14.5549
Table 1 Relationship between clinical pathological parameters and nm23H1 genetic instability in gastric cancer
Clinical pathological factors | Cases (n) | MSI+ (%) | LOH+ (%) | nm23H1+ (%) | nm23H1 expression intensity (mean ± SD) |
Histological type | 40 | 8 (20.00) | 7 (17.50) | 22 (55.00) | 40.63 ± 2.95 |
Tubular adenocarcinoma | 33 | 7 (22.21) | 6 (18.18) | 21 (63.64) | 41.56 ± 2.78 |
High differentiation | 10 | 3 (30.00) | 1 (10.00) | 10 (100.00) | 41.83 ± 1.52 |
Middle differentiation | 15 | 3 (20.00) | 2 (13.33) | 9 (60.00) | 40.69 ± 2.35 |
Low differentiation | 8 | 1 (12.50) | 3 (37.50) | 2 (25.00)1 | 41.43 ± 1.89 |
Mucoid adenocarcinoma | 7 | 1 (14.29) | 1 (14.29) | 1 (14.29)2 | 39.87 ± 2.31 |
Serosa infiltration | |||||
Positive | 24 | 3 (12.50) | 6 (25.00) | 10 (41.67) | 39.76 ± 2.64 |
Negative | 16 | 5 (31.25) | 1 (6.25) | 12 (75.00)3 | 41.45 ± 2.23 |
Lymph node metastasis | |||||
Positive | 20 | 1 (5.00) | 6 (30.00) | 6 (30.00) | 39.14 ± 2.34 |
Negative | 20 | 7 (35.00)4 | 1 (5.00)5 | 16 (80.00)6 | 41.75 ± 1.65 |
TNM stage | |||||
I+ II | 22 | 7 (31.82) | 1 (4.55) | 17 (77.27) | 41.22 ± 1.87 |
III + IV | 18 | 1 (5.56)7 | 6 (33.33)8 | 5 (17.86)9 | 40.13 ± 2.35 |
Table 2 Relationship between MSI, LOH and nm23H1 protein expression in different cancers of digestive system
Group | Positive frequency of nm23H1 protein % (n/n) | |||
Gastric cancer | Colon cancer | HCC | Gallbladder cancer | |
MSI positive | 87.50 (7/8) | 75.00 (6/8) | 83.33 (5/6) | 63.64 (7/11) |
MSI negative | 46.88 (15/32)1 | 45.45 (10/22) | 52.38 (22/42) | 41.67 (15/36) |
LOH positive | 14.29 (1/7) | 33.33 (2/6) | 27.27 (3/11) | 11.11 (1/9) |
LOH negative | 63.64 (21/33)2 | 58.33 (14/24) | 64.86 (24/37)3 | 55.26 (21/38)4 |
Table 3 Relationship between MSI, LOH and nm23H1 protein expression in different cancers of digestive system (mean ± SD)
Group | nm23H1 protein expression intensity (n = 10) | |||
Gastric cancer | Colon cancer | HCC | Gallbladder cancer | |
MSI positive | 26.34 ± 2.17 | 29.34 ± 2.14 | 29.34 ± 2.14 | 26.34 ± 2.17 |
MSI negative | 25.78 ± 2.34 | 24.78 ± 2.06 | 24.78 ± 2.06 | 25.78 ± 2.34 |
LOH positive | 27.64 ± 2.38 | 22.64 ± 2.38 | 22.64 ± 2.38 | 27.64 ± 2.38 |
LOH negative | 25.88 ± 2.52 | 26.88 ± 2.52 | 26.88 ± 2.52 | 25.88 ± 2.52 |
Table 4 Relationship between clinical pathological parameters and nm23H1 genetic instability in colon cancer
Clinical pathological factors | Cases | MSI+ (%) | LOH+ (%) | nm23H1+ (%) | nm23H1 expression intensity (mean ± SD) |
Histological type | 30 | 8 (26.67) | 6 (20.00) | 16 (53.33) | 40.21 ± 3.29 |
Tubular adenocarcinoma | 25 | 7 (28.00) | 5 (20.00) | 15 (60.00) | 40.76 ± 2.74 |
High differentiation | 8 | 2 (25.00) | 1 (12.50) | 8 (100.00) | 41.49 ± 2.01 |
Middle differentiation | 13 | 5 (38.46) | 2 (15.38) | 6 (46.15) | 40.41 ± 1.98 |
Low differentiation | 4 | 0 (00.00) | 2 (50.00) | 1 (25.00)1 | 40.18 ± 2.17 |
Mucoid adenocarcinoma | 5 | 1 (20.00) | 1 (20.00) | 1 (20.00) | 39.53 ± 2.61 |
Serosa infiltration | |||||
Positive | 20 | 7 (35.00) | 3 (15.00) | 12 (48.00) | 41.02 ± 2.14 |
Negative | 10 | 1 (10.00) | 3 (30.00) | 4 (40.00) | 41.45 ± 2.23 |
Lymph node metastasis | |||||
Positive | 11 | 1 (9.09) | 5 (45.45) | 3 (27.27) | 39.14 ± 2.34 |
Negative | 19 | 7 (36.84) | 1 (5.26)2 | 13 (68.42)3 | 41.75 ± 1.65 |
TNM stage | |||||
I+ II | 16 | 7 (43.75) | 1 (11.76) | 13 (81.25) | 41.49 ± 2.01 |
III + IV | 14 | 1 (7.14)4 | 5 (35.71)5 | 3 (21.43)6 | 39.53 ± 2.61 |
Table 5 Relationship between clinical pathological parameters and nm23H1 genetic instability in HCC
Clinical pathological factors | Cases | MSI+ (%) | LOH+ (%) | nm23H1+ (%) | nm23H1 expression intensity (mean ± SD) |
Differentiation degree | 48 | 6 (12.50) | 11 (22.92) | 27 (56.25) | 25.96 ± 2.53 |
High differentiation | 15 | 3 (20.00) | 2 (13.33) | 10 (66.67) | 27.87 ± 2.83 |
Middle differentiation | 20 | 2 (10.00) | 5 (25.00) | 12 (60.00) | 22.37 ± 2.35 |
Low differentiation | 13 | 1 (7.70) | 4 (30.77) | 5 (38.46) | 22.58 ± 2.56 |
Liver infiltration | |||||
Positive | 15 | 0 (00.00) | 8 (53.33) | 6 (40.00) | 23.84 ± 2.43 |
Negative | 33 | 6 (18.18) | 3 (9.09) | 21 (63.64) | 25.63 ± 2.63 |
Lymph node metastasis | |||||
Positive | 20 | 1 (5.00) | 9 (45.00) | 4 (20.00) | 21.67 ± 2.56 |
Negative | 28 | 5 (17.86) | 2 (7.14) | 23 (82.14)1 | 28.56 ± 2.01 |
TNM stage | |||||
I+ II | 29 | 5 (17.24) | 1 (3.45) | 22 (75.86) | 25.58 ± 2.33 |
III + IV | 19 | 1 (5.26) | 10 (52.63)2 | 5 (26.32)2 | 24.27 ± 2.27 |
Table 6 Relationship between clinical pathological parameters and nm23H1 genetic instability in gallbladder cancer
Clinical pathological factors | Cases | MSI + (%) | LOH + (%) | nm23H1 + (%) | nm23H1 expression intensity (mean ± SD) |
Differentiation degree | 47 | 11 (22.40) | 9 (19.14) | 22 (46.81) | 25.96 ± 2.73 |
High differentiation | 17 | 9 (52.94) | 0 (00.00) | 10 (58.82) | 24.15 ± 2.49 |
Middle differentiation | 13 | 2 (15.38) | 3 (23.08) | 7 (53.85) | 27.07 ± 2.53 |
Low differentiation | 17 | 0 (00.00)1 | 6 (35.29)2 | 5 (29.41) | 28.03 ± 2.63 |
Liver infiltration | |||||
Positive | 18 | 1 (5.56) | 7 (38.89) | 6 (33.33) | 24.87 ± 2.83 |
Negative | 29 | 10 (34.48)3 | 2 (6.90)4 | 16 (55.17) | 26.37 ± 2.45 |
lymph node metastasis | |||||
Positive | 20 | 1 (5.00) | 8 (40.00) | 5 (25.00) | 23.56 ± 2.19 |
Negative | 27 | 10 (37.04)5 | 1 (3.70)6 | 17 (62.96)7 | 26.67 ± 2.33 |
TNM stage | |||||
I+ II | 23 | 10 (43.48) | 0 (00.00) | 15 (65.22) | 24.15 ± 2.78 |
III + IV | 24 | 1 (4.17)8 | 9 (37.50)9 | 7 (29.17)10 | 29.84 ± 2.53 |
- Citation: Yang YQ, Wu L, Chen JX, Sun JZ, Li M, Li DM, Lu HY, Su ZH, Lin XQ, Li JC. Relationship between nm23H1 genetic instability and clinical pathological characteristics in Chinese digestive system cancer patients. World J Gastroenterol 2008; 14(36): 5549-5556
- URL: https://www.wjgnet.com/1007-9327/full/v14/i36/5549.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.5549